By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Newron Pharmaceuticals 

Via R. Lepetit
Gerenzano      Italy
Phone: 39-02-9668131 Fax: 39-02-96681333



Company News
Newron Pharma (NWRN) To Re-Submit U.S. NDA For Xadago (Safinamide) 7/26/2016 10:28:19 AM
Newron Pharma (NWRN) Announces Initiation Of The STARS Study In The United States 7/21/2016 9:41:49 AM
Newron Pharma (NWRN) To Evaluate Burden Of Disease For Rett Syndrome Patients And Families 6/27/2016 11:02:31 AM
Newron Pharma (NWRN) To Present STARS Trial Design At U.S. Rett Syndrome Symposium 6/16/2016 7:53:30 AM
Newron Pharma (NWRN) To Present At The Jefferies 2016 Healthcare Conference In New York 5/25/2016 10:52:20 AM
Newron Pharma (NWRN) Announces IND Approval For Sarizotan For Treatment Of Rett Syndrome 5/17/2016 11:29:50 AM
Newron Pharma (NWRN) And Partner Zambon Support Parkinson's Disease Awareness Day 2016 4/11/2016 8:20:10 AM
Newron Pharma (NWRN) Release: Ongoing Phase II Study Of Evenamide (NW-3509) May Suggest An Alternative Approach To The Treatment Of Schizophrenia 4/5/2016 10:34:21 AM
FDA Wants Additional Evaluation of Newron Pharma (NWRN)'s Xadago 3/30/2016 8:08:42 AM
Newron Pharmaceuticals (NWRN) Release: Evenamide (NW-3509): Evidence Of Anti-Psychotic Efficacy As An Add-On To Antipsychotics In Ongoing Phase 2 Study May Suggest An Alternative Approach To The Treatment Of Schizophrenia 3/23/2016 9:56:07 AM